breast-neoplasms

Documents about breast-neoplasms

• A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer#435753ClinicalTrials.gov
• Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity#855490ClinicalTrials.gov
• To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients#888218ClinicalTrials.gov
• Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen#900079ClinicalTrials.gov
• PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY#907942ClinicalTrials.gov
• Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma#890958ClinicalTrials.gov
• ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies#1007335ClinicalTrials.gov
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)#812612ClinicalTrials.gov
• Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer#991811ClinicalTrials.gov
• Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients#804125ClinicalTrials.gov
• Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions#826020ClinicalTrials.gov
• Risk factor of young breast cancer: A multicenter study#441420USM Repository
• Comparison of Pain Therapeutic Effects After Benign Mastectomy#994083ClinicalTrials.gov
• Identifying shared polygenic risk across cancers#1001757PLOS
• Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma#378270Lund University Publications
• Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse#843119ClinicalTrials.gov
• Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.#909379ClinicalTrials.gov
• Telehealth Program to Prevent Cancer and Chemotherapy-related Cognitive Impairment.#918532ClinicalTrials.gov
• Clinical, pathological, treatment, and follow-up data of patients with triple-negative breast cancer treated with carboplatin-containing neoadjuvant chemotherapy#443363Repositório de Dados de Pesquisa da Unicamp Dataverse OAI Archive
• Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab#827092ClinicalTrials.gov
• Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®#918726ClinicalTrials.gov
• A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer#813109ClinicalTrials.gov
• PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan#837798ClinicalTrials.gov
• Usage Of Artificial Intelligence-Integrated Usg In Application of Pectoral Block In Mastectomies#855353ClinicalTrials.gov
• Socioeconomic inequalities in adherence to clinical practice guidelines and breast cancer survival: a multicentre population-based study in Spain.#455671Repisalud
• Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea#887517ClinicalTrials.gov
• The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.#966135ClinicalTrials.gov
• Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors#865626ClinicalTrials.gov
• A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer#833876ClinicalTrials.gov
• The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach#880843ClinicalTrials.gov
• Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies#897169ClinicalTrials.gov
• Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy#226245ClinicalTrials.gov
• Role of genetic variations of parp1 polymorphisms on triple negative breast cancer (TNBC) susceptibility risk#279008USM Repository
• Women Underwent TRAM Surgery: Its Influence on Abdominal Muscle Function and the Effects of Therapeutic Exercises#880742ClinicalTrials.gov
• Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.#892374ClinicalTrials.gov
• Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer#803444ClinicalTrials.gov
• Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor#184845ClinicalTrials.gov
• A new cancer progression model: From synthetic tumors to real data and back#309473PLOS
• The Oncological Safety and Cosmetic Outcome of Areola Sparing Mastectomy : a Single Arm, Prospective, Cohort Study#812135ClinicalTrials.gov
• Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC#875804ClinicalTrials.gov
• Exploring Biological Linkage Between Circadian Disruption and Cancer Progression#887989ClinicalTrials.gov
• Realist Collaborative Evaluation of a Work Disability Prevention Program for Breast Cancer Survivors: Protocol for a RECOVA-FASTRACS Realist Evaluation#922930HAL (France)
• Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer#127593ClinicalTrials.gov
• Replication gap suppression depends on the double-strand DNA binding activity of BRCA2#291404Gestión del Repositorio Documental de la Universidad de Salamanca
• The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.#889897ClinicalTrials.gov
• Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.#872927ClinicalTrials.gov
• A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer#881006ClinicalTrials.gov
• Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients#859688ClinicalTrials.gov
• Epitranscriptomic mechanisms in prostate and breast cancer#990185University of Nottingham Repository
• Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers#179022Lund University Publications